中文名称: CDKI-73
英文名称: CDKI-73
CAS No: 1421693-22-2
分子式: C15H15FN6O2S2
分子量: 394.45
C10824 CDKI-73 ≥98% (psaitong)
包装规格:
1mg 5mg 10mg 25mg 50mg 100mg in glass bottle
溶解性:
溶于DMSO(≥ 52 mg/mL 超声)
产品描述:

基本信息

产品编号:C10824

产品名称:CDKI-73

CAS:

1421693-22-2

 

储存条件

粉末

2-8℃

四年

分子式:

C15H15FN6O2S2

溶于液体

-80℃

两年

分子量

394.45

-20℃

一个月

化学名: 

3-((5-fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)benzenesulfonamide

 

Solubility (25°C)

 

体外

DMSO

79mg/mL (200.27mM)

Ethanol

1.5mg/mL (3.8mM)

Water

Insoluble

体内

现配现用

 

1mg/ml表示微溶或不溶。

普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。

 

 

制备储备液

 

浓度

 

溶液体积

质量

 

1mg

 

5mg

 

10mg

1mM

2.5352mL

12.6759mL

25.3518mL

5mM

0.5070mL

2.5352mL

5.0704mL

10mM

0.2535mL

1.2676mL

2.5352mL

50mM

0.0507mL

0.2535mL

0.5070mL

 

 

生物活性

产品描述

具有口服活性的、高效的 CDK9 抑制剂,其对CDK9、CDK1 和 CDK2 的 Ki 值分别为 4nM、4nM 和 3nM。

靶点/IC50

CDK2 
(Cell-free assay)

CDK9 
(Cell-free assay)

CDK1 
(Cell-free assay)

CDK4 
(Cell-free assay)

3.27nM

5.78nM

8.17nM

8.18nM

 

体外研究

CDKI-73 is highly cytotoxic to primary leukemia cells derived from CLL patients (mean LD50 = 0.08μM) and shows>500-fold selectivity for primary leukemia cells over normal B-lymphocytes (LD50 = 40.5μM).

CDKI-73 (0.1μM, 4 h) inhibits the phosphorylation of serine 2 of RNA polymerase II and MCL1 protein expression in CLL cells.

CDKI-73 induced caspase-dependent apoptosis that was preceded by dephosphorylation of cdk9 and serine 2 of RNA polymerase II.

CDKI-73 is highly effective against all cell lines tested with an IC50 in the range of 0.012-0.517μM; in particular three MLLAML cell lines, namely MOLM13, MV4-11 and THP-1, were highly sensitive to CDKI-73 with IC50 values <0.062μM.

Cell Viability Assay.

Cell Line:

CLL cells.

Concentration:

0-1μM.

Incubation Time:

48 h.

Result:

Shows preferential cytotoxicity in CLL cells.

 

体内研究

CDKI-73 (25, 50, 100 mg/kg) markedly decreases tumor growth in a dose-dependent manner and results in a prolongation of animal life span (P < 0.001) without causing body weight loss and other overt toxicities.

Animal Model:

MV4-11 tumor bearing mice .

Dosage:

25mg/kg.

Administration:

Orally once everyday for 33 days.

Result:

Caused a remarkable delay in tumor growth compared to vehicle-treated mice, as reflected in a percentage for the mean tumor volume in treated to control mice of 43% at day 31.

 

Animal Model:

Balb/C mice aged 6-8 weeks.

Dosage:

2mg/kg (IV), 10, 20 and 40mg/kg (PO). (Pharmacokinetic Analysis.)

Administration:

IV and PO, single dose.

Result:

The Cmax increased from 1.29 to 3.66μM at a mean time of 1 h and the area under the curve (AUC) of CDKI-73 increased from 3.51 to 12.8μM.h when the oral dose was escalated from 10 to 40mg/kg.

CDKI-73 was eliminated from plasma with a mean terminal half-life (T1/2) of 2 h. Its oralbioavailability (F) ranged from 54 to 85% across the three doses.

保存条件:
2-8℃ 充氮保存
UN码:
HazardClass:
危害声明:
安全说明:
搜索质检报告(COA)
参考文献 & 客户发表文献

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • =
    *
    *
    *选择对应的单位 *空出希望得到的变量,填写另外两个变量

用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )

  • * = *

连续稀释计算器方程

  • 连续稀释

  • 初始浓度:
  • 稀释倍数:
  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):